ReviewHeart failure reviews2021
Cardiac contractility modulation for patient with refractory heart failure: an updated evidence-based review.
Review in Heart failure reviews, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Novel device-based and catheter-directed therapies for heart failure with preserved ejection fraction.Cardiovascular intervention and therapeutics · 2026Review
- Advances in Diagnosis and Treatment of Acute and Chronic Heart Failure: A Comprehensive Review.Journal of clinical medicine · 2026Review
- Efficacy of Contractility Modulation Therapy in Patients with Transthyretin Amyloid Cardiomyopathy, Mildly Reduced to Reduced EF and NYHA III and IV: A Multicentric, Prospective Pilot Study for AMY-CCM Registry.Journal of cardiovascular development and disease · 2025Article
- Novel Medical Treatments and Devices for the Management of Heart Failure with Reduced Ejection Fraction.Journal of cardiovascular development and disease · 2024Review
- Transcriptional response of the heart to vagus nerve stimulation.Physiological genomics · 2024Article
- Cost-utility of cardiac contractility modulation in patients with heart failure with reduced ejection fraction in Italy.ESC heart failure · 2024Article
- Advances in device-based treatment of heart failure with preserved ejection fraction: evidence from clinical trials.ESC heart failure · 2024Review
- Transcriptional response of the heart to vagus nerve stimulation.Physiological genomics · 2024Article
- Current Approaches to Worsening Heart Failure: Pathophysiological and Molecular Insights.International journal of molecular sciences · 2024Review
- Clinical evidence and potential mechanisms of traditional Chinese medicine for refractory heart failure: a literature review and perspectives.Frontiers in cardiovascular medicine · 2024Review
- Review
- Cardiac Contractility Modulation Therapy in Patients with Amyloid Cardiomyopathy and Heart Failure, Case Report, Review of the Biophysics of CCM Function, and AMY-CCM Registry Presentation.Journal of clinical medicine · 2023Article
- Should HFrEF patients with NYHA class II expect benefit from CCM therapy? Results from the MAINTAINED observational study.Clinical research in cardiology : official journal of the German Cardiac Society · 2022Observational
- Continuous Renal Replacement Therapy for Hypertension Complicated by Refractory Heart Failure: An Analysis of Safety and Nursing Highlights.Computational and mathematical methods in medicine · 2022Article
- Cardiac contractility modulation ameliorates myocardial metabolic remodeling in a rabbit model of chronic heart failure through activation of AMPK and PPAR-α pathway.Open medicine (Warsaw, Poland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure is the cardiovascular epidemic of the twenty-first century, with poor prognosis and quality of life despite optimized medical treatment. Despite over the last decade significant improvements, with a major impact on morbidity and mortality, have been made in therapy for heart failure with reduced ejection fraction, little progress was made in the development of devices, with the implantable defibrillator indicated for patients with left ventricle ejection fraction ≤ 35% and cardiac resynchronization therapy for those with QRS ≥ 130 ms and evidence of left bundle branch block. Nevertheless, only a third of patients meet these criteria and a high percentage of patients are non-responders in terms of improving symptoms. Nowadays, in patients with symptomatic heart failure with ejection fraction between 25% and 45% and QRS < 130 ms, not eligible for cardiac resynchronization, the cardiac contractility modulation (CCM) represents a concrete therapeutic option, having proved to be safe and effective in reducing hospitalizations for heart failure and improving symptoms, functional capacity, and quality of life. The aim of this review is therefore to summarize the pathophysiological mechanisms, the current indications, and the recent developments regarding the new applications of the CCM for patients with chronic heart failure.
Indexed as
Identifiers
32974722What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.